Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02569398 · ClinicalTrials.gov registry record · Phase 2
An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia
A Phase 2 study, sponsored by Janssen Research & Development.
- Terminated
- Registry status
- Phase 2
- Development phase
- 557
- Enrollment target
NCT02569398 is a Phase 2 study that was terminated before completion, run by Janssen Research & Development. The registered enrollment target is 557 participants.
The verdict
NCT02569398, a Phase 2 study, was terminated before completion, sponsored by Janssen Research & Development.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 557 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether treatment with atabecestat slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive Composite (PACC), in amyloid-positive participants who are asymptomatic at risk for developing Alzheimer's dementia.
Interventions
- DRUG Placebo
- DRUG Atabecestat, 5 mg
- DRUG Atabecestat, 25 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 557 participants |
| Start Date | 2015-10-29 |
| Est. Completion | 2018-12-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02569398
The ClinicalTrials.gov registry entry for NCT02569398 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 557 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02569398 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02569398 about?
NCT02569398 is a clinical study titled "An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia". The purpose of this study is to evaluate whether treatment with atabecestat slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive Composite (PACC), in amyloid-positive participants who are asymptomatic at risk for d...
What is the current status of trial NCT02569398?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 557 participants. The study started on 2015-10-29. Estimated completion is 2018-12-20.
What interventions are being tested in trial NCT02569398?
The interventions under investigation include: Placebo (DRUG), Atabecestat, 5 mg (DRUG), Atabecestat, 25 mg (DRUG).
Who is sponsoring clinical trial NCT02569398?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.